Literature DB >> 20401607

Kinase cascades and ligand-directed signaling at the kappa opioid receptor.

Michael R Bruchas1, Charles Chavkin.   

Abstract

BACKGROUND AND RATIONALE: The dynorphin/kappa opioid receptor (KOR) system has been implicated as a critical component of the stress response. Stress-induced activation of dynorphin-KOR is well known to produce analgesia, and more recently, it has been implicated as a mediator of stress-induced responses including anxiety, depression, and reinstatement of drug seeking.
OBJECTIVE: Drugs selectively targeting specific KOR signaling pathways may prove potentially useful as therapeutic treatments for mood and addiction disorders.
RESULTS: KOR is a member of the seven transmembrane spanning (7TM) G-protein coupled receptor (GPCR) superfamily. KOR activation of pertussis toxin-sensitive G proteins leads to Galphai/o inhibition of adenylyl cyclase production of cAMP and releases Gbetagamma, which modulates the conductances of Ca(+2) and K(+) channels. In addition, KOR agonists activate kinase cascades including G-protein coupled Receptor Kinases (GRK) and members of the mitogen-activated protein kinase (MAPK) family: ERK1/2, p38 and JNK. Recent pharmacological data suggests that GPCRs exist as dynamic, multi-conformational protein complexes that can be directed by specific ligands towards distinct signaling pathways. Ligand-induced conformations of KOR that evoke beta-arrestin-dependent p38 MAPK activation result in aversion; whereas ligand-induced conformations that activate JNK without activating arrestin produce long-lasting inactivation of KOR signaling.
CONCLUSIONS: In this review, we discuss the current status of KOR signal transduction research and the data that support two novel hypotheses: (1) KOR selective partial agonists that do not efficiently activate p38 MAPK may be useful analgesics without producing the dysphoric or hallucinogenic effects of selective, highly efficacious KOR agonists and (2) KOR antagonists that do not activate JNK may be effective short-acting drugs that may promote stress-resilience.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20401607      PMCID: PMC3671863          DOI: 10.1007/s00213-010-1806-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  109 in total

Review 1.  MAPK cascade signalling and synaptic plasticity.

Authors:  Gareth M Thomas; Richard L Huganir
Journal:  Nat Rev Neurosci       Date:  2004-03       Impact factor: 34.870

2.  kappa-opioid receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative effect of opioids.

Authors:  J A Gurwell; M J Duncan; K Maderspach; A Stiene-Martin; R P Elde; K F Hauser
Journal:  Brain Res       Date:  1996-10-21       Impact factor: 3.252

Review 3.  Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

4.  Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor.

Authors:  Carol Smith; Tariq Rahman; Nicole Toohey; Joseph Mazurkiewicz; Katharine Herrick-Davis; Milt Teitler
Journal:  Mol Pharmacol       Date:  2006-07-26       Impact factor: 4.436

5.  Regulation of cocaine reward by CREB.

Authors:  W A Carlezon; J Thome; V G Olson; S B Lane-Ladd; E S Brodkin; N Hiroi; R S Duman; R L Neve; E J Nestler
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

6.  Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding.

Authors:  K L Pierce; A Tohgo; S Ahn; M E Field; L M Luttrell; R J Lefkowitz
Journal:  J Biol Chem       Date:  2001-04-04       Impact factor: 5.157

7.  Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord.

Authors:  H N Bhargava; A Gulati; P Ramarao
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

8.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

9.  SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons.

Authors:  Gavin Rumbaugh; J Paige Adams; Jee H Kim; Richard L Huganir
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

10.  Molecular mechanisms of agonist-induced desensitization of the cloned mouse kappa opioid receptor.

Authors:  K Raynor; H Kong; J Hines; G Kong; J Benovic; K Yasuda; G I Bell; T Reisine
Journal:  J Pharmacol Exp Ther       Date:  1994-09       Impact factor: 4.030

View more
  137 in total

1.  Kappa-opioid receptor agonist U50448H protects against renal ischemia-reperfusion injury in rats via activating the PI3K/Akt signaling pathway.

Authors:  Li-Jie Liu; Jian-Jun Yu; Xiao-Lin Xu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons.

Authors:  Kelly A Berg; Matthew P Rowan; Achla Gupta; Teresa A Sanchez; Michelle Silva; Ivone Gomes; Blaine A McGuire; Philip S Portoghese; Kenneth M Hargreaves; Lakshmi A Devi; William P Clarke
Journal:  Mol Pharmacol       Date:  2011-11-09       Impact factor: 4.436

Review 3.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

4.  6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.

Authors:  Marie-Laure Rives; Mary Rossillo; Lee-Yuan Liu-Chen; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

5.  The therapeutic potential of κ-opioids for treatment of pain and addiction.

Authors:  Charles Chavkin
Journal:  Neuropsychopharmacology       Date:  2011-01       Impact factor: 7.853

6.  Tracking down the molecular substrates of stress: new roles for p38α MAPK and kappa-opioid receptors.

Authors:  John W Muschamp; Ashlee Van't Veer; William A Carlezon
Journal:  Neuron       Date:  2011-08-11       Impact factor: 17.173

Review 7.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

Review 8.  Influence of stress associated with chronic alcohol exposure on drinking.

Authors:  Howard C Becker
Journal:  Neuropharmacology       Date:  2017-04-19       Impact factor: 5.250

9.  κ Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake.

Authors:  Timothy W Whitfield; Joel E Schlosburg; Sunmee Wee; Adam Gould; Olivier George; Yanabel Grant; Eva R Zamora-Martinez; Scott Edwards; Elena Crawford; Leandro F Vendruscolo; George F Koob
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

10.  Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.

Authors:  Antony D Abraham; Selena S Schattauer; Kathryn L Reichard; Joshua H Cohen; Harrison M Fontaine; Allisa J Song; Salina D Johnson; Benjamin B Land; Charles Chavkin
Journal:  J Neurosci       Date:  2018-08-03       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.